M5717   

GtoPdb Ligand ID: 9737

Synonyms: DDD107498 | DDD498 | MMV121
Compound class: Synthetic organic
Comment: M5717 (formerly DDD498) is a quinoline-4-carboxamide derivative that is the optimised lead developed from a phenotypic screen for novel antimalarial drugs and has advanced to clinical evaluation. The compound was awarded MMV Project of the Year (2014).

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 57.7
Molecular weight 462.24
XLogP 3.43
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES Fc1ccc2c(c1)c(cc(n2)c1ccc(cc1)CN1CCOCC1)C(=O)NCCN1CCCC1
Isomeric SMILES Fc1ccc2c(c1)c(cc(n2)c1ccc(cc1)CN1CCOCC1)C(=O)NCCN1CCCC1
InChI InChI=1S/C27H31FN4O2/c28-22-7-8-25-23(17-22)24(27(33)29-9-12-31-10-1-2-11-31)18-26(30-25)21-5-3-20(4-6-21)19-32-13-15-34-16-14-32/h3-8,17-18H,1-2,9-16,19H2,(H,29,33)
InChI Key BENUHBSJOJMZEE-UHFFFAOYSA-N
Guide to Malaria Pharmacology Comments
M5717 has comparable activity against multiple stages of the malaria parasite lifecycle and is indicated for use as a combination therapy for acute uncomplicated malaria, with potential to be a single dose treatment [1].
The compound is example 1A from patent WO2013153357 [2].

Potential Target/Mechanism Of Action: Evidence from genetic experiments indicates that P. falciparum elongation factor 2 (PfeEF2) may be the molecular target [1].
Target Candidate Profiles
Profile Intended Use Target Stage Comment References
TCP-1 reduce parasite burden asexual blood stages 1
TCP-4 chemoprotection hepatic schizonts 1
TCP-5 transmission reduction gametocytes 1